Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial

@article{Rllig2014TwoCO,
  title={Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial},
  author={Christoph R{\"o}llig and Kerstin Sch{\"a}fer-Eckardt and Matthias Haenel and Michael Kramer and Markus Schaich and Christian Thiede and Uta Oelschlaegel and Brigitte Mohr and Thomas Wagner and Hermann Einsele and Stefan W Krause and Heinrich Bodenstein and Sonja Martin and Reingard Stuhlmann and Antony Dick Ho and Martin Bornhaeuser and Gerhard Ehninger and Ulrich S. Schuler and Uwe- Platzbecker},
  journal={Annals of Hematology},
  year={2014},
  volume={94},
  pages={557-563}
}
The combination of all-trans retinoic acid (ATRA) and idarubicin (AIDA) for induction therapy followed by three cycles of risk-adapted consolidation cycles is considered standard of care for patients with acute promyelocytic leukemia (APL). We report the outcome of 141 patients (median age 51 years; range, 19–82, 31 % ≥60 years) enrolled into the… CONTINUE READING